VivoSeq
Dermatology

Vitiligo

73

Pipeline Programs↗

45

Active Trials↗

39

Companies Involved↗

Vitiligo is a moderately active landscape with 73 programs across 39 companies. The most active players are Forte Biosciences, Inc., Teva, Sun Pharmaceutical Industries, Inc.. 13 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

46/100

Mech. Concentration

16/100

Completion Rate

83/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Forte Biosciences, Inc.

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Sun Pharmaceutical Industries, Inc. logo

Sun Pharmaceutical Industries, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1LEO Pharma logo

LEO Pharma

1 program

Phase 1C

Clinuvel Pharmaceuticals Limited

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical11

Beclomethasone

Chiesi Farmaceutici S.p.A.

Tretinoin

Valeant Pharmaceuticals

Ibuprofen

Kenvue Brands

Fluticasone Propionate

GSK

Systemic Steroids

University Hospital, Bordeaux

Phase 112

Tildrakizumab

Sun Pharmaceutical Industries, Inc.

Bimatoprost

AbbVie

Abatacept

Bristol-Myers Squibb

Tofacitinib

Prism Pharmaceuticals

Azathioprine

Legacy Health System

Phase 229

Deucravacitinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Triamcinolone

Bassett Healthcare

Metformin Hydrochloride

Boehringer Ingelheim

Anifrolumab

AstraZeneca

Simvastatin

Organon and Co

Phase 38

Ritlecitinib

Pfizer

Upadacitinib

AbbVie

Tacrolimus

Veloxis Pharmaceuticals

Povorcitinib

Incyte

Oral Mini Pulse

South Valley University

Approved13

Secukinumab

Novartis

Ruxolitinib

Incyte

Latanoprost

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Pimecrolimus

Bausch Health Americas, Inc.

Dexamethasone

Aspen Global Incorporated

Analysis

Modality Breakdown

93%

Small molecule

90 of 97 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody33%Protein / enzyme33%Peptide11%

Small molecule leads; the ring shows all 97 classified programs, each share of the total. Modality classified for 97% of 104 pipeline programs.

Analysis

Trial Status

128

clinical trials

Completed54 · 42%
Recruiting25 · 20%
Unknown status18 · 14%
Active, not recruiting11 · 9%
Terminated7 · 5%
Not yet recruiting7 · 5%
Other6 · 5%

Clinical Trials

Trial Activity

128 trials

Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Recruiting·HHospital Authority, Hong Kong·Phase 2/3·NCT06719024·20 enrolled
A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo
Recruiting·CCAGE Bio Inc.·Phase 1·NCT07357870·36 enrolled
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
Recruiting·HHudson Biotech·Phase 2·NCT07437560·60 enrolled
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 2·NCT07172347·120 enrolled
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07251595·176 enrolled
Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo
Recruiting·—·Phase 1·NCT07398807·40 enrolled
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Recruiting·Incyte logoIncyte·Phase 3·NCT06804811·250 enrolled
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Recruiting·Pfizer logoPfizer·Phase 3·NCT06163326·400 enrolled
Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT05927272·10 enrolled
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
Recruiting·PPeking University Third Hospital·N/A·NCT07153666·170 enrolled
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
Recruiting·—·Phase 2·NCT07105254·20 enrolled
Vitiligo, New Treatment and Serum s100B
Recruiting·SSouth Valley University·Phase 2/3·NCT06768840·50 enrolled
Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo
Recruiting·—·Phase 4·NCT05536856·60 enrolled
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Recruiting·Takeda logoTakeda·Phase 2·NCT07108283·200 enrolled
Oral Mini Pulse Dexamethasone in Pediatric Vitiligo
Recruiting·—·Phase 4·NCT07353801·22 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)